Immunovant, Inc.
Immunovant, Inc. (IMVT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IMVT · as of Jun 8, 2026
Key Statistics
Explore Immunovant, Inc. Data
imvt stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 23 · Buy rate: 78.3%
The IMVT analyst consensus is Buy, based on ratings from 23 Wall Street analysts over the past 3 months. The average 12-month price target is $43.67, representing +41.79% upside from the current price of $30.80.
Competitors & Peers
imvt competitorsIMVT
ACAD
AKRO
CRNX
DYN
KYMRStock Performance
Full HistoryAbout Immunovant, Inc.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The compa…
what is immunovant, inc. · imvt stock overview · immunovant, inc. company profile · who is immunovant, inc. ceo · imvt NASDAQ · immunovant, inc. headquarters · immunovant, inc. business segments
About Stock Overview & Key Data
Immunovant, Inc. (IMVT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 21, 2019. As of the latest trading session, IMVT stock price is $30.80, with a market capitalization of $6.3B. The stock has returned +90.73% over the past 12 months and +22.23% year-to-date.
According to 23 Wall Street analysts, the consensus rating for Immunovant, Inc. stock is Buy, with an average 12-month price target of $43.67. In fiscal year 2026, Immunovant, Inc. reported revenue of — and net income of -$505.6M. For detailed data — including Immunovant, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Immunovant, Inc. (IMVT) stock price is $30.80. The stock is traded on NASDAQ under the ticker symbol IMVT. The 52-week range is $14.32 – $36.28.